Progyny Inc. is a fertility benefits management company based in the United States. The company was founded in 2015 and is headquartered in New York City. Progyny's primary goal is to provide comprehensive fertility benefits and support to individuals and couples seeking assisted reproductive technology (ART) treatments. Progyny Inc. is listed on the Nasdaq Stock Market under the ticker symbol "PGNY."
Progyny partners with employers to offer fertility benefits as part of their employee benefit packages. The company's mission is to help individuals and couples navigate their fertility journey by providing them with access to high-quality fertility treatments, advanced reproductive technologies, and emotional support. Progyny's services include diagnostic testing, in vitro fertilization (IVF), egg freezing, genetic testing, and surrogacy support.
Progyny Access is a comprehensive fertility benefit program that provides members with access to a network of fertility clinics, high-quality care, and personalized support throughout their fertility journey. The program covers a wide range of fertility treatments and services, including fertility preservation, fertility medications, and fertility counseling.
Progyny's approach stands out for its emphasis on personalized care and patient support. The company assigns each member a dedicated patient care advocate who serves as a single point of contact, guiding them through their treatment options, answering questions, and coordinating their care. This personalized approach helps alleviate the stress and complexity often associated with fertility treatments.
Additionally, Progyny leverages advanced data analytics to drive better outcomes and cost efficiencies. The company collects and analyzes extensive data on treatment outcomes, provider performance, and patient experiences. This data-driven approach enables Progyny to continually improve its services, optimize treatment protocols, and negotiate favorable rates with its network of fertility clinics.